Biocon Claims Edge For Adalimumab In US
Cites Encouraging Payer Discussions Over Humira Biosimilar
Biocon, which is set to close its deal with Viatris shortly, says it is in a “very good position” to vie for a share of the adalimumab biosimilar pie in the US and has had encouraging preliminary discussions with payers.
You may also be interested in...
Biocon has achieved a milestone after its Biocon Biologics subsidiary closed its $3bn deal to acquire the biosimilars business of longtime partner Viatris, in what management described as a “historic inflection point” for the Indian player.
Biocon Biologics is continuing to rack up the capital needed to close its multi-billion deal for Viatris’ global biosimilars business, with two quick equity investments from parent Biocon Limited as stipulated under its acquisition agreement.
Recently public Alvotech had much to share as part of its nine-month financial report, including updates on adalimumab in the US and the process to begin biosimilar golimumab trials.